Data gathered: November 18
AI Stock Analysis - Novo Nordisk (NVO)
Analysis generated November 18, 2024. Powered by Chat GPT.
Novo Nordisk, headquartered in Denmark, is a global healthcare company with nearly a century of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk’s products are marketed in more than 170 countries, reflecting its expansive footprint and impact on global health.
Stock Alerts - Novo Nordisk (NVO)
 |
Novo Nordisk | November 15 Michael McCaul (member of U.S. congress) is buying shares |
|
Novo Nordisk | November 10 AI Score is up by 20.2% in the last couple of days. |
|
Novo Nordisk | October 31 Reddit mentions are up by 325% in the last 24h. |
|
Novo Nordisk | October 13 AI Score is up by 22% in the last couple of days. |
Alternative Data for Novo Nordisk
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $99.81 |
| Target Price | Sign up |
| Volume | 8,570,000 |
| Market Cap | $473B |
| Year Range | $99.81 - $146.35 |
| Dividend Yield | 1.42% |
| PE Ratio | 34.03 |
| Analyst Rating | 67% buy |
| Industry | Drug Manufacturers |
In the news
 |
Novo Nordisk To Offer Wegovy In China At Fraction Of USA CostNovember 18 - Biztoc.com |
Novo Nordisk A/S - share repurchase programmeNovember 18 - GlobeNewswire |
|
 |
Novo Nordisk launches Wegovy in China with prices well below U.SNovember 18 - Biztoc.com |
 |
Novo Nordisk launches Wegovy in China with prices well below U.S.November 18 - Fortune |
 |
A stronger Ozempic is coming. What to know about CagriSema, Novo Nordisk's new weight loss drugNovember 18 - Quartz India |
 |
Novo Nordisk A/S (NVO) Trembled At The End Of The QuarterNovember 14 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 0 | 0 | 0 | 0 | 0.900 |
| Q2 '24 | 68.1B | 10.3B | 57.8B | 20.1B | 34.8B | 0.660 |
| Q1 '24 | 65.3B | 9.92B | 55.4B | 25.4B | 35.3B | 0.830 |
| Q4 '23 | 65.9B | 10B | 55.8B | 22B | 28.5B | 0.710 |
| Q3 '23 | 58.7B | 9.71B | 49B | 22.5B | 29.4B | 0.730 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$154.77 0.5% | 51 |
 |
Eli Lilly and CompanyLLY |
$727.2 2.5% | 63 |
 |
PfizerPFE |
$24.86 0.2% | 51 |
 |
AstrazenecaAZN |
$63.39 0.3% | 68 |
 |
AbbVieABBV |
$166.28 0.8% | 59 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul |
Nov 14, 24 | Buy | $15K - $50K |
| John James |
Sep 2, 24 | Buy | $1K - $15K |
| Michael McCaul |
Jun 20, 24 | Buy | $15K - $50K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novo Nordisk?
The Market Cap of Novo Nordisk is $473B.
What is Novo Nordisk's PE Ratio?
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 34.03.
What is the current stock price of Novo Nordisk?
Currently, the price of one share of Novo Nordisk stock is $99.81.
How can I analyze the NVO stock price chart for investment decisions?
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Does NVO offer dividends to its shareholders?
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 1.42%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Novo Nordisk?
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.